Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia

---

Autoria(s): Garderet L.; Iacobelli S.; Moreau P.; Onida F.; Koenecke C.; Scheid C.; Doyen C.; Bouko Y.; Ketterer N.; Masszi T.; Crawley C.; Hajek R.; Linkesch W.; Ludwig H.; Harousseau J.L.; Michalet M.; De Witte T.; Niederwieser D.; Gahrton G.; Morris C.

Data(s)	2010
Identificador	http://serval.unil.ch/?id=serval:BIB_5735726CA210
Idioma(s)	en
Fonte	36th Annual Meeting of the European Group for Blood and Marrow Transplantation
Tipo	info:eu-repo/semantics/conferenceObject inproceedings